GlassScriptPhysician profile
Gordon B Greaves
NPI 1699708131
$2,175.96
in general payments reported to CMS, 2019-2025
14 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.52 · 2023: $409 · 2024: $1,246 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.17 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $580.91 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $375.90 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $339.88 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $248.83 | 2023-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $232.91 | 2023-2025 | Lybalvi, Aristada |
| Corium, LLC | $113.90 | 2023-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.99 | 2023-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $62.44 | 2023-2024 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $34.87 | 2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
| Lundbeck LLC | $23.54 | 2025 | Rexulti |
| Tris Pharma INC | $21.75 | 2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $16.25 | 2024 | Qelbree |
| Novo Nordisk INC | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Greaves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.